Company profile
TENAX THERAPEUTICS, INC.
NASDAQ:TENXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LEVOSIMENDAN | phase3 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03541603 | phase2 | completed | 2018-11-14 | 2020-04-07 | Tenax Therapeutics, Inc. | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF |
| NCT07288398 | phase3 | recruiting | 2026-03-03 | 2028-06-30 | Tenax Therapeutics, Inc. | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 |
| NCT05983250 | phase3 | active_not_recruiting | 2024-01-10 | 2026-06-30 | Tenax Therapeutics, Inc. | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF |
| NCT02025621 | phase3 | completed | 2014-07-01 | 2016-11-01 | Tenax Therapeutics, Inc. | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass |
| NCT07436689 | phase3 | enrolling_by_invitation | 2026-03-13 | 2029-03-01 | Tenax Therapeutics, Inc. | Long-Term Open-Label Extension Study of Oral Levosimendan |
FDA applications (0)
No records yet.